Improving anxiety-induced insomnia with lavender oil
New data shows pharmaceutical-quality lavender oil significantly improves anxiety-induced insomnia when taken as a daily capsule.
Pharmaceutical-quality lavender oil has a significant anxiolytic (anxiety relieving) effect and improves insomnia when taken orally as a daily capsule, new data shows.
Disturbed sleep is a prevalent symptom in anxiety disorders and a key diagnosis criterion for subthreshold and generalised anxiety disorders (GAD). It is estimated that more than two thirds of patients with GAD suffer from insomnia, with even higher rates amongst the elderly, causing a detrimental effect on patients’ daily living skills and quality of life. In 80% of patients with diagnosed anxiety disorders, symptoms of insomnia appear simultaneously with anxiety symptoms(5) highlighting the importance of targeting insomnia in the treatment of anxiety.
Pharmacological anxiety treatments such as benzodiazepines carry a sedating effect. Although some patients may see a short-term improvement in sleep, common side effects of benzodiazepine use include daytime drowsiness and rebound insomnia – further intensifying sleep disturbances. Benzodiazepines can also cause a physical dependence and withdrawal reaction when taken for longer than the recommended 4 weeks, a common withdrawal symptom is insomnia making it hard for patients to break the anxiety-insomnia cycle.
A mediation analysis by researchers from the Universities of Zurich and Basel published this month in the Journal of Psychiatric Research, found that 98.4% of patients saw an improvement in anxiety-related sleep disturbances when taking a daily capsule of pharmaceutical quality lavender oil vs placebo. The results indicate that pharmaceutical quality lavender oil exerts a secondary sleep improving effect almost exclusively through its anxiety-relieving action rather than by sedation(.
Pharmaceutical quality lavender oil capsules are shown to decrease excessive neurotransmitter activity, reducing overstimulation and hyperactivity of the nervous response - improving symptoms of mild anxiety. More than 15 clinical trials show that a daily lavender oil capsule can be AS EFFECTIVE as commonly used anti-anxiety medication, including the benzodiazepine lorazepam prescribed in GAD without the risk of sedation, dependency or withdrawal.
Professor of Psychiatry, Professor Hans-Peter Volz comments: ‘’This is a positive development for anxiety. Research demonstrates that the lavender oil capsules reduce both physical and psychological symptoms of anxiety (including sleep disturbances), without issues such as sedation, addiction or withdrawal. Lavender oil capsules provide a promising alternative treatment option to prescription drugs for subthreshold anxiety sufferers.”
The anxiety-relieving effects of uniquely prepared, pharmaceutical quality lavender oil are available only in Kalms Lavender One-A-Day Capsules.
Nicky Lidbetter, CEO of Anxiety UK states: ‘’Anxiety is one of the most prevalent mental health conditions in the UK - one in five people report feeling anxious a lot or all of the time; and more than 45 million working days have been lost due to anxiety (combined with depression and stress) in the past three years. We welcome a range of treatment and support options, including the Kalms Lavender One-a-Day capsule and other non-prescription options such as talking therapies.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance